Pregnancy, Breastfeeding, and GLP-1 Medications: What You Need to Know

GLP-1 Medications and Pregnancy Safety

• ⚠️ Current recommendations advise a two-month washout period before attempting pregnancy after using GLP-1 medications.
• 📊 Data on safety during pregnancy is mixed, with animal studies showing increased risks of fetal growth issues and birth defects.
• 💡 However, a large study of women who were accidentally on these medications before knowing they were pregnant showed no increased risk of birth defects in approximately 50,000 women.
• ❓ The definitive answer on safety during pregnancy is still unclear due to insufficient data.

Breastfeeding and GLP-1 Use

• 🔬 A small study indicated that semaglutide (the medication in Ozempic and Wegovy) was not detected in breast milk.
• ✅ This suggests it may be safe for breastfeeding, but further research is needed as the jury is still out.

Postpartum Use and Research Gaps

• 🎯 GLP-1 medications are effective for weight loss, with clinical trials showing 15-20% body weight reduction.
• ⚠️ Crucially, none of these trials specifically focused on postpartum women, highlighting a significant gap in research.
• 🚫 Women's health research, especially concerning women of color who are at higher risk for obesity and postpartum issues, is under-researched and may be impacted by current administrative policies.

Trust, Access, and Conflicts of Interest

• 💬 Serena Williams' openness about using GLP-1s for weight loss after childbirth is brave and helps destigmatize obesity.
• 💰 However, her role as a paid spokesperson and her husband's investor status raise questions about conflicts of interest.
• 📉 A significant barrier to access is cost, as Medicaid does not cover these medications, meaning about 40% of women who go through pregnancy cannot afford them.
• ⚖️ This creates a huge gap in need versus accessibility for these powerful weight-loss drugs.